Results 1 to 10 of about 5,245,251 (341)

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial [PDF]

Lancet, The, 2019
Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage.
Rustam Al-Shahi Salman, Colin Baigent, Daniel Lasserson   +2 more
exaly   +4 more sources

Rationale and design of a randomised double-blind 2×2 factorial trial comparing the effect of a 3-month intensive statin and antiplatelet therapy for patients with acute mild ischaemic stroke or high-risk TIA with intracranial or extracranial atherosclerosis (INSPIRES)

Stroke and Vascular Neurology, 2023
Background It remains unclear if intensive antiplatelet and statin treatments begun within 24–72 hours of cerebral ischaemic events from intracranial or extracranial atherosclerosis is effective or safe.Methods The Intensive Statin and Antiplatelet ...
Liping Liu, Yongjun Wang, Yilong Wang, Xingquan Zhao, Chunjuan Wang, Jing Jing, Philip M Bath, Hao Li, Xia Meng, Weiqi Chen, Yuesong Pan, S Claiborne Johnston, Pierre Amarenco, Ying Gao, Tingting Wang, Shangrong Han, Yingying Yang   +16 more
doaj   +2 more sources

Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy

Frontiers in Cardiovascular Medicine, 2022
Dual antiplatelet therapy with a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) and aspirin remains the standard of care for all patients undergoing percutaneous coronary intervention (PCI).
Anh B. Nguyen, Larisa H. Cavallari, Joseph S. Rossi, George A. Stouffer, Craig R. Lee, Craig R. Lee   +5 more
doaj   +2 more sources

Antiplatelet Therapy in Heart Disease [PDF]

Reviews in Cardiovascular Medicine
Antiplatelet therapy plays a pivotal role in the management of atherosclerotic cardiovascular diseases, providing critical protection against thrombotic complications.
Nil Ozyuncu
doaj   +2 more sources

Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk.

New England Journal of Medicine, 2021
BACKGROUND The appropriate duration of dual antiplatelet therapy in patients at high risk for bleeding after the implantation of a drug-eluting coronary stent remains unclear.
M. Valgimigli, E. Frigoli, D. Heg, J. Tijssen, P. Jüni, P. Vranckx, Y. Ozaki, M. Morice, B. Chevalier, Y. Onuma, S. Windecker, P. Tonino, M. Roffi, M. Lesiak, F. Mahfoud, J. Bartunek, D. Hildick-Smith, A. Colombo, G. Stanković, A. Íñiguez, C. Schultz, R. Kornowski, P. Ong, M. Alasnag, Alfredo E. Rodríguez, Aris Moschovitis, P. Laanmets, M. Donahue, S. Leonardi, P. Smits   +29 more
semanticscholar   +1 more source

Dual Antiplatelet Therapy vs Alteplase for Patients With Minor Nondisabling Acute Ischemic Stroke: The ARAMIS Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2023
Importance Intravenous thrombolysis is increasingly used in patients with minor stroke, but its benefit in patients with minor nondisabling stroke is unknown.
Hui-Sheng Chen, Yu Cui, Zhong-he Zhou, Hong Zhang, Li-xia Wang, Wei-zhong Wang, Li-Ying Shen, Li-yan Guo, E. Wang, Ruixian Wang, Jing Han, Yuming Dong, Jing Li, Yongzhong Lin, Qing-Cheng Yang, L. Zhang, Jingye Li, Jin Wang, Lei Xia, Guangbin Ma, Jiang Lu, Chang-Hao Jiang, Shuchun Huang, Lishu Wan, Xiang-yu Piao, Zhuo Li, Yan-song Li, Kui-hua Yang, Duo-Lao Wang, Thanh N. Nguyen   +29 more
semanticscholar   +1 more source

Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.

JAMA cardiology, 2022
Importance Clopidogrel monotherapy after short dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) has not yet been fully investigated in patients with acute coronary syndrome (ACS).
Hirotoshi Watanabe, T. Morimoto, M. Natsuaki, Ko Yamamoto, Y. Obayashi, M. Ogita, S. Suwa, T. Isawa, T. Domei, K. Yamaji, Shojiro Tatsushima, Hiroki Watanabe, M. Ohya, H. Tokuyama, T. Tada, H. Sakamoto, Hiroyoshi Mori, Hiroshi Suzuki, Tenjin Nishikura, K. Wakabayashi, K. Hibi, M. Abe, K. Kawai, K. Nakao, K. Ando, K. Tanabe, Y. Ikari, Y. Morino, K. Kadota, Y. Furukawa, Y. Nakagawa, T. Kimura   +31 more
semanticscholar   +1 more source

Precision antiplatelet therapy

Research and Practice in Thrombosis and Haemostasis, 2023
A State of the Art lecture titled "Personalizing Antiplatelet Therapy Based on Platelet Turnover and Metabolic Phenotype" was presented by Bianca Rocca at the International Society on Thrombosis and Haemostasis (ISTH) Congress in 2022. Increased variability in drug response may be associated with serious, mechanism-based and off-target side effects ...
Rocca, Bianca, Patrono, Carlo
openaire   +2 more sources

Dual Antiplatelet Therapy: A Concise Review for Clinicians

Life, 2023
Dual antiplatelet therapy (DAPT) combines two antiplatelet agents to decrease the risk of thrombotic complications associated with atherosclerotic cardiovascular diseases. Emerging data about the duration of DAPT is being published continuously.
H. H. Virk, Johao Escobar, Mario Rodriguez, E. Bates, U. Khalid, H. Jneid, Y. Birnbaum, Glenn N. Levine, Sidney C. Smith, C. Krittanawong   +9 more
semanticscholar   +1 more source

Bleeding and thrombosis outcomes in hospitalised COVID-19 patients on low-molecular-weight heparin and antiplatelet therapy

South African Medical Journal, 2022
Background. An increased incidence of thromboembolic events in hospitalised COVID‐19 patients has been demonstrated despite the use of low‐molecular‐weight heparin (LMWH).
V Pillay-Fuentes Lorente, R van Rensburg, M S Moolla, M McCaul, A Parker, J Taljaard, H Reuter, E H Decloedt   +7 more
doaj   +1 more source